{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:11:38Z","timestamp":1780438298497,"version":"3.54.1"},"update-to":[{"DOI":"10.1002\/14651858.cd003685","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2005,1,24]],"date-time":"2005-01-24T00:00:00Z","timestamp":1106524800000}}],"reference-count":32,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003685.pub2","type":"journal-article","created":{"date-parts":[[2005,1,26]],"date-time":"2005-01-26T15:50:44Z","timestamp":1106754644000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Rofecoxib for rheumatoid arthritis"],"prefix":"10.1002","volume":"2010","author":[{"given":"Sarah E","family":"Garner","sequence":"first","affiliation":[{"name":"National Institute for Clinical Excellence; Appraisals Team; MidCity Place 71 High Holborn London UK WC1V 6NA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dogan","family":"Fidan","sequence":"additional","affiliation":[{"name":"Aventis Pharma Ltd.; Health Economics Unit; Flat 8 291 Boardwalk Place London UK E14 56E"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth R","family":"Frankish","sequence":"additional","affiliation":[{"name":"National Institute for Clinical Excellence; Appraisals Team; MidCity Place 71 High Holborn London UK WC1V 6NA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Judd","sequence":"additional","affiliation":[{"name":"Canadian Health Services Research Foundation\/Fondation canadienne de la recherche sur les services de sant\u00e9; Research Use\/Agente principale de programme, Utilisation de la Recherche; 1565 avenue Carling Avenue Suite\/pi\u00e8ce 700 Ottawa Ontario Canada K1Z 8R1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanveer","family":"Towheed","sequence":"additional","affiliation":[{"name":"Queen's University; Department of Medicine and of Community Health and Epidemiology; Etherington Hall-Room 2066 Kingston Ontario Canada K7L 3N6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[{"name":"Ottawa Hospital; Centre for Global Health, Institute of Population Health, Department of Medicine; 1 Stewart Street Ottawa Ontario Canada K1N 6N5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A","family":"Wells","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute; Cardiovascular Research Reference Centre; Room H1-1 40 Ruskin Street Ottawa Ontario Canada K1Y 4W7"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,1,24]]},"reference":[{"issue":"21","key":"10.1002\/14651858.CD003685.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of Rofecoxib and Naproxen in patients with rheumatoid arthritis. The VIGOR trial","volume":"343","author":"Bombardier","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD003685.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S0149-2918(99)80048-4","article-title":"The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group","volume":"21","author":"Schnitzer","year":"1999","journal-title":"Clinical Therapeutics"},{"issue":"9","key":"10.1002\/14651858.CD003685.pub2-BIB0003|cit3","first-page":"1670-Abstract 2","article-title":"COX-2 specific inhibition with MK-096625 or 50 mg Q.D. does not increase intestinal permeability [abstract]","volume":"93","author":"Bjarnason","year":"1998","journal-title":"American journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD003685.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1046\/j.1365-2036.1999.00529.x","article-title":"Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen","volume":"13","author":"Lanza","year":"1999","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"10","key":"10.1002\/14651858.CD003685.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0149-2918(99)80045-9","article-title":"Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial","volume":"21","author":"Malmstrom","year":"1999","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD003685.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/gut.47.4.527","article-title":"Cox-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double-blind cross-over study comparing rofecoxib with placebo and indomethacin","volume":"47","author":"Sigthrosson","year":"2000","journal-title":"GUT"},{"key":"10.1002\/14651858.CD003685.pub2-BIB0007|cit7","unstructured":"6 week placebo controlled study 137 patients (125mg rofecoxib 175mg rofecoxib versus placebo). Centre for Drug Evaluation and Research (CDER017) plus extension"},{"issue":"820-826","key":"10.1002\/14651858.CD003685.pub2-BIB0008|cit8","article-title":"Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen or placebo: a multicentre, randomised, double blind study","volume":"52","author":"Hawkey","year":"2003","journal-title":"Gut"},{"key":"10.1002\/14651858.CD003685.pub2-BIB0009|cit9","unstructured":"Phase IIb dose finding study. 2 year duration 634 patients comparing 25 50 mg rofecoxib to naproxen placebo. Details in Konstam 2001"},{"key":"10.1002\/14651858.CD003685.pub2-BIB0010|cit10","unstructured":"Phase III: domestic US 1 year duration 909 patients. Comparing 12.5 25 50mg rofecoxib with naproxen placebo. Details in Konstam 2001"},{"key":"10.1002\/14651858.CD003685.pub2-BIB0011|cit11","unstructured":"Phase III international study. 1058 enrolled 1 year duration. Rofecoxib 25 50mg compared to naproxen placebo. Details in Konstam 2001"},{"key":"10.1002\/14651858.CD003685.pub2-BIB0012|cit12","unstructured":"Measurement of clinical outcome within clinical service Ongoing study"},{"issue":"1","key":"10.1002\/14651858.CD003685.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000046212","article-title":"Renal effects of COX-2-selective inhibitors","volume":"21","author":"Brater","year":"2001","journal-title":"American Journal of Nephrology"},{"key":"10.1002\/14651858.CD003685.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)90944-Z","article-title":"Blood presure, stroke and coronary disease, II: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context","volume":"335","author":"Collins","year":"1990","journal-title":"Lancet"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD003685.pub2-BIB0015|cit15","first-page":"S143-Abstract 4","article-title":"Cardiovascular safety profile of rofecoxib in controlled clinical trials","volume":"42","author":"Daniels","year":"1999","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD003685.pub2-BIB0016|cit16","unstructured":"FDA Advisory Committee Cardiovascular safety review of rofecoxib http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/3677b2_06_cardio.pdf"},{"key":"10.1002\/14651858.CD003685.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD003685.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD003685.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomised controlled trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD003685.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"r15","DOI":"10.1161\/hc4401.100078","article-title":"Cardiovascular thrombotic events in controlled clinical trials of rofecoxib","volume":"104","author":"Konstam","year":"2001","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD003685.pub2-BIB0021|cit21","first-page":"526","article-title":"Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials","volume":"20","author":"OMERACT","year":"1993","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1002\/14651858.CD003685.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/1529-0131(199908)42:8<1572::AID-ANR2>3.0.CO;2-G","article-title":"ACR20: clinical or statistical significance?","volume":"42","author":"Pincus","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1002\/14651858.CD003685.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"9272","DOI":"10.1016\/S0140-6736(00)05083-2","article-title":"Acute tubulointerstitial nephritis associated wiht the selective COX II enzyme inhibitor rofecoxib","volume":"357","author":"Rocha","year":"2001","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD003685.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD003685.pub2-BIB0025|cit25","first-page":"811","article-title":"Epidemiology and rheumatic diseases","volume-title":"Oxford Textbook of Rheumatology","author":"Silman","year":"1998"},{"key":"10.1002\/14651858.CD003685.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","article-title":"Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving NSAIDs: a randomised double-blind, placebo controlled trial","volume":"123","author":"Siverstein","year":"1995","journal-title":"Annals of Internal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD003685.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD003685.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-133-1-200007040-00002","article-title":"Effect of cyclooxygenase -2 inhibition on renal function in elderly persons receiving a low salt diet: a randomised controlled trial","volume":"133","author":"Swan","year":"2000","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD003685.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.pharmtox.38.1.97","article-title":"Cyclooxygenases 1 and 2","volume":"38","author":"Vane","year":"1998","journal-title":"Annual Review of Pharmacology & Toxicology"},{"key":"10.1002\/14651858.CD003685.pub2-BIB0030|cit30","first-page":"2562","article-title":"Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset","volume":"26","author":"Wallberg-Jonsson","year":"1999","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD003685.pub2-BIB0031|cit31","article-title":"Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee","author":"Watson","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003685.pub2-BIB0032|cit32","doi-asserted-by":"crossref","DOI":"10.1097\/00045391-200103000-00003","article-title":"Cyclo-oxygenase-2 specific inhibitors and cardio-renal function: a randomised controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients","volume":"8","author":"Whelton","year":"2001","journal-title":"American Journal of Therapeutics"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD003685.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T14:01:16Z","timestamp":1641304876000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003685.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2005,1,24]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2010,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003685.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,24]]}}}